SUBSTITUTE SEQUENCE LISTING

<110>	HI UI W	OUGEC UAULN NGEHE ISNEF UFOUR	ME, S EUER, R, Ai	Jean- , Mai nne	-Frai rie-l	ncois										
<120>	P F	EPTII OR S <i>i</i>	DES 1	DERIY PEPT:	VED I	FROM AND	HUM	AN BI	PLP I	PROTI	EIN, CTED	POL'S	YNUCI INST	CEOT	DES COD	ING ES
<130>	2	9641	5US0	PCT												
		US 10/593,071 2006-09-15														
		PCT/IB05/00700 2005-03-18														
		EPO 04290754.3 2004-03-19														
<160>	1	15														
<170>	P	PatentIn version 3.3														
<210><211><211><212><222><221><222>	9 D	47 NA Iomo	_													
<400> aattg			tggc	aaga	.g ta	ıagat	taac	, cag	ıtaat	ttg	ttcc	aaag	jaa g	aatc	ttcta	60
ccaag	ggag	gca a	cttt	aaag	ga at Me 1	g aa et Ly	a tt 's Le	a ac eu Th	t tt ir Ph 5	c tt le Ph	c tt le Le	g gg eu Gl	ıc ct .y Le	g tt eu Le 10	g gct u Ala	113
ctt a Leu I	att [le	tca Ser	tgt Cys 15	ttc Phe	aca Thr	ccc Pro	agt Ser	gag Glu 20	agt Ser	caa Gln	aga Arg	ttc Phe	tcc Ser 25	aga Arg	aga Arg	161
cca t Pro 1	tat Tyr	cta Leu 30	cct Pro	ggc Gly	cag Gln	ctg Leu	cca Pro 35	cca Pro	cct Pro	cca Pro	ctc Leu	tac Tyr 40	agg Arg	cca Pro	aga Arg	209
tgg g Trp V	gtt Val 15	cca Pro	cca Pro	agt Ser	ccc Pro	cca Pro 50	cct Pro	ccc Pro	tat Tyr	gac Asp	tca Ser 55	aga Arg	ctt Leu	aat Asn	tca Ser	257
cca o Pro I 60																305

tct cga Ser Arg	a ttt g Phe	agc Ser	caa Gln 80	gca Ala	gtc Val	att Ile	cta Leu	tct Ser 85	caa Gln	ctc Leu	ttt Phe	cca Pro	ttg Leu 90	gaa Glu	353
tct att	aga a Arg	caa Gln 95	cct Pro	cga Arg	ctc Leu	ttt Phe	ccg Pro 100	ggt Gly	tat Tyr	cca Pro	aac Asn	cta Leu 105	cat His	ttc Phe	401
cca cta Pro Lei	a aga u Arg 110	Pro	tac Tyr	tat Tyr	gta Val	gga Gly 115	cct Pro	att Ile	agg Arg	ata Ile	tta Leu 120	aaa Lys	ccc Pro	cca Pro	449
ttt cc Phe Pro	o Pro	att Ile	cct Pro	ttt Phe	ttt Phe 130	ctt Leu	gct Ala	att Ile	tac Tyr	ctt Leu 135	cct Pro	atc Ile	tct Ser	aac Asn	497
cct ga Pro Gl	g ccc u Pro	caa Gln	ata Ile	aac Asn 145	atc Ile	acc Thr	acc Thr	gca Ala	gat Asp 150	aca Thr	aca Thr	atc Ile	acc Thr	aca Thr 155	545
aat cc Asn Pr	c ccc o Pro	acc Thr	act Thr 160	Ala	aca Thr	gca Ala	acc Thr	acc Thr 165	Arg	cac His	ttc Phe	cac His	aaa Lys 170	Thr	593
cac aa His As	t gac n Asp	gat Asp 175	Gln	ctc Leu	ctc Leu	aac Asn	agt Ser 180	Thr	tat Tyr	ctc Leu	ttc Phe	aac Asn 185	Thr	aga Arg	641
gcc tg Ala Cy		Leu					Asn					Tyr			686
aaatactact caaattctcg ccaaccgtcc tcacacagta ttgctcaatg ccactgtcca												746			
agttacgact tccaaccaaa ctatattaag cagcccagcc													806		
actctttgcc atttttggtt gaacatgcaa taaatgatat tttccaaact gctctgatat													866		
cttagaagaa ataaactgca atgattttga tggaaccaac cctgatctaa ccagcacact													926		
aaataaagta tttgagcaat a												947			

<210> 2

<211> 201

<212> PRT

<213> Homo sapiens

<400> 2

Met Lys Leu Thr Phe Phe Leu Gly Leu Leu Ala Leu Ile Ser Cys Phe 1 5 10 15

Thr Pro Ser Glu Ser Gln Arg Phe Ser Arg Arg Pro Tyr Leu Pro Gly 20 25 30

Gln Leu Pro Pro Pro Pro Leu Tyr Arg Pro Arg Trp Val Pro Pro Ser 35 40 45

Pro Pro Pro Tyr Asp Ser Arg Leu Asn Ser Pro Leu Ser Leu Pro 50 55 60

Phe Val Pro Gly Arg Val Pro Pro Ser Ser Phe Ser Arg Phe Ser Gln 70 75 80

Ala Val Ile Leu Ser Gln Leu Phe Pro Leu Glu Ser Ile Arg Gln Pro 85 90 95

Arg Leu Phe Pro Gly Tyr Pro Asn Leu His Phe Pro Leu Arg Pro Tyr 100 110

Tyr Val Gly Pro Ile Arg Ile Leu Lys Pro Pro Phe Pro Pro Ile Pro 115 120 125

Phe Phe Leu Ala Ile Tyr Leu Pro Ile Ser Asn Pro Glu Pro Gln Ile 130 135 140

Asn Ile Thr Thr Ala Asp Thr Thr Ile Thr Thr Asn Pro Pro Thr Thr 145 150 155 160

Ala Thr Ala Thr Thr Arg His Phe His Lys Thr His Asn Asp Asp Gln
165 170 175

Leu Leu Asn Ser Thr Tyr Leu Phe Asn Thr Arg Ala Cys His Leu His
180 185 190

Ile Ser Ser Asn Pro Arg Ser Ile Tyr 195 200

<210> 3

<211> 5

<212> PRT

<213> Homo sapiens

<400> 3

Gln Arg Phe Ser Arg
1 5

```
<210> 4
<211> 6
<212> PRT
<213> Homo sapiens
<400> 4
Tyr Gln Arg Phe Ser Arg
1
<210> 5
<211> 6
<212> PRT
<213> Homo sapiens
<400> 5
Cys Gln Arg Phe Ser Arg
1
<210> 6
<211>
<212> PRT
<213> Homo sapiens
<220>
<221>
       MISC_FEATURE
<222>
       (1)..(2)
<223> Xaa2 is Gln or Glp when Xaa1 is not present.
       Xaa2 is Gln when Xaa1 is Tyr or Cys.
<400> 6
Xaa Xaa Arg Phe Ser Arg
<210> 7
<211> 5
<212> PRT
<213> Homo sapiens
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaal is Glp.
<400> 7
Xaa Arg Phe Ser Arg
```

```
<210>
<211>
<212> PRT
<213> Rattus rattus
<400> 8
Gln His Asn Pro Arg
1
<210> 9
<211>
      4
<212> PRT
<213> Rattus rattus
<400> 9
Gln His Asn Pro
1
<210>
       10
<211>
       5
<212>
      PRT
<213> Homo sapiens
<400>
      10
Gln Arg Gly Pro Arg
1
<210> 11
<211> 7
<212> PRT
<213> Homo sapiens
<400> 11
Gln Arg Gly Pro Arg Gly Pro
1
                5
<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
       Synthetic Construct
<223>
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Arg at position 1 is modified with (7-methoxycoumarin-4-yl)acetyl
```

```
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> hydroxy substituted 2,4-dinitrophenyl amino acid
<400> 12
Arg Pro Pro Gly Phe Ser Ala Phe Lys Xaa
                                   10
                5
1
<210> 13
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Construct
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Ala at position 1 is modified with succinyl
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Phe at position 3 is modified with 7-amino-4-methyl coumarin
<400> 13
Ala Ala Phe
<210> 14
<211> 11
<212> PRT
<213> Homo sapiens
<400> 14
Arg Phe Lys Phe Gln Gln Phe Phe Gly Leu Met
                                    10
 <210> 15
 <211> 5
 <212> PRT
 <213> Homo sapiens
 <400> 15
 Tyr Gly Gly Phe Met
```